

Patient Name: MR. VENKATRAMANAN N

Age / Gender: 36 years / Male

Patient ID: 96635

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:31 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

000916122

			000910122
Test Description	Value(s)	Reference Range	
COMPLETE BLOOD COUNT (CBC)			
Hemoglobin (Hb)	13.5	13.5 - 18.0	gm/dL
Erythrocyte (RBC) Count	4.79	4.7 - 6.0	mil/cu.mm
Packed Cell Volume (PCV)	41.0	42 - 52	%
Mean Cell Volume (MCV)	85.59	78 - 100	fL
Mean Cell Haemoglobin (MCH)	28.18	27 - 31	pg
Mean Corpuscular Hb Concn. (MCHC)	32.93	32 - 36	g/dL
Red Cell Distribution Width (RDW)	13.2	11.5 - 14.0	%
Total Leucocytes (WBC) Count	7200	4000-10000	cell/cu.mm
Neutrophils	53	40 - 80	%
Lymphocytes	37	20 - 40	%
Monocytes	7	2 - 10	%
Eosinophils	3	1 - 6	%
Basophils	0	1-2	%
Absolute Neutrophil Count	3816	2000 - 7000	/c.mm
Absolute Lymphocyte Count	2664	1000 - 3000	/c.mm
Absolute Monocyte Count	504	200 - 1000	/c.mm
Absolute Eosinophil Count	216	20 - 500	/c.mm
Absolute Basophils Count	0	20 - 100	/c.mm
Platelet Count	312	150 - 450	10^3/ul
Mean Platelet Volume (MPV)	9.1	7.2 - 11.7	fL
РСТ	0.28	0.2 - 0.5	%
PDW	9.4	9.0 - 17.0	%
ESR	30.0	13.5 - 18.0	mm/hr

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MR. VENKATRAMANAN N

Age / Gender: 36 years / Male

Patient ID: 96635

Referral: MediWheel

Collection Time: Jun 10, 2022, 09:31 a.m. Reporting Time: Jun 10, 2022, 01:56 p.m.

Sample ID:

Test Description Value(s) Reference Range

URINE COMPLETE ANALYSIS,

Physical Examination

Quantity 30 - ml

Colour Pale Yellow Pale yellow/Yellow

Appearance Clear Clear

 Specific Gravity
 1.020
 1.005-1.025

 pH
 6.0
 5.0 - 8.0


 Deposit
 Present
 Absent

Chemical Examination

Protein Absent Absent Sugar Absent Absent **Ketones** Absent Absent **Bile Salt** Absent Absent **Bile Pigment** Absent Absent Urobilinogen Normal Normal

Microscopic Examination (/hpf)

Pus Cell Upto 5 1-2 1-2 **Epithelial Cells** Upto 5 **Red Blood Cells** Absent Absent Casts Absent Absent Crystals Absent Absent **Amorphous Deposit** Absent Absent **Yeast Cells** Absent Absent **Bacteria** Absent Absent Other findings Not seen Not seen



Scan to Validate



Page 2 of 11



Patient Name: MR. VENKATRAMANAN N

Age / Gender: 36 years / Male

Patient ID: 96635

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:31 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

Test Description

Value(s)

Reference Range

END OF REPORT







Patient Name: MR. VENKATRAMANAN N

Age / Gender: 36 years / Male

Patient ID: 96635

Referral: MediWheel

Collection Time: Jun 10, 2022, 09:31 a.m.

Reporting Time : Jun 10, 2022, 01:56 p.m.

Sample ID:

Test Description	Value(s) Reference Range		
Glycosylated HbA1c			
HbA1c (GLYCOSYLATED HEMOGLOBIN),	6.4		%
BLOOD			
Method : (HPLC, NGSP certified)			
Estimated Average Glucose :	136.98	-	mg/dL
Interpretation			
As per American Diabetes Association (ADA)			
Reference Group	HbA1c in %		
Non diabetic adults >=18 years	<5.7		
At risk (Prediabetes)	5.7 - 6.4		
Diagnosing Diabetes	>= 6.5		
	Age > 19 year	rs	
	Goal of therap	py: < 7.0	
Therapeutic goals for glycemic control	Action sugges	sted: > 8.0	
	Age < 19 year	rs	

Note:

 Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled.

Goal of therapy: <7.5

Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant
cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid
conditions, targeting a goal of < 7.0 % may not be appropriate.

Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

Scan to Validate



Page 4 of 11



Patient Name: MR. VENKATRAMANAN N

Age / Gender: 36 years / Male

Patient ID: 96635

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:31 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

Test Description

Value(s)

Reference Range

ADA criteria for correlation between HbA1c & Mean plasma glucose levels.

HbA1c(%)	Mean Plasma Glucose (mg/dL)
6	126
7	154
8	183
9	212
10	240
11	269
12	298

END OF REPORT







Patient Name: MR. VENKATRAMANAN N

Age / Gender: 36 years / Male

Patient ID: 96635

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:31 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
LIPID PROFILE			
Cholesterol-Total Method : Spectrophotometry	226.0	Desirable level < 200 Borderline High 200-239 High >or = 240	mg/dL
Triglycerides Method : Serum, Enzymatic, endpoint	472.0	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	mg/dL
HDL Cholesterol Method : Serum, Direct measure-PEG	40.0	Normal: > 40 Major Risk for Heart: < 40	mg/dL
LDL Cholesterol Method : Enzymatic selective protection	91.60	Optimal < 100 Near / Above Optimal 100-129 Borderline High 130-159 High 160-189 Very High >or = 190	mg/dL
VLDL Cholesterol Method : Serum, Enzymatic	94.40	6 - 38	mg/dL
CHOL/HDL Ratio Method : Serum, Enzymatic	5.65	3.5 - 5.0	
LDL/HDL Ratio Method : Serum, Enzymatic Note:	2.29	2.5 - 3.5	
8-10 hours fasting sample is required.			

END OF REPORT

SAROJINI.K MBBS.,DCP.,

Scan to Validate



Page 6 of 11



Patient Name: MR. VENKATRAMANAN N

Age / Gender: 36 years / Male

Patient ID: 96635

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:31 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

.0	6.3-8.2 3.5-5.0 1.8 - 3.6 1.2 - 2.2	g/dL g/dL g/dL
.0	3.5-5.0 1.8 - 3.6	g/dL
-0	1.8 - 3.6	
-0	1.8 - 3.6	
		g/dL
		g/dL
8	1.2 - 2.2	
88	1.2 - 2.2	
}	0.3-1.2	mg/dL
	< 0.2	mg/dL
i	0.1 - 1.0	mg/dL
.0	17-59	U/L
.0	21-72	U/L
1.0	30 - 120	U/L
.0	< 55	U/L
	0 0 1.0	< 0.2 0.1 - 1.0 0 17-59 0 21-72 1.0 30 - 120

END OF REPORT







Patient Name: MR. VENKATRAMANAN N

Age / Gender: 36 years / Male

Patient ID: 96635

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:31 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

000916122

Test Description	Value(s)	Reference Range	
RENAL PROFILE			
Urea	19.0	19-42	mg/dL
Method : Uricase			
Blood Urea Nitrogen-BUN	8.87	9-20	mg/dL
Method : Serum, Urease			
Creatinine	0.81	0.66-1.25	mg/dL
Method : Serum, Jaffe			
Uric Acid	9.1	3.5-8.5	mg/dL
Method : Serum, Uricase			
Remark:			
In blood, Urea is usually reported as BL	JN and expressed in mg/dl.	BUN mass units can be conver	ted to urea mass units by
multiplying by 2.14.	•		•

END OF REPORT

DR.UMA SAROJINI.K MBBS.,DCP.,





Patient Name: MR. VENKATRAMANAN N

Age / Gender: 36 years / Male

Patient ID: 96635

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:31 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
THYROID PROFILE TEST - TOTAL			
T3-Total	88.0	60 - 200	ng/dL
T4-Total	10.0	4.52 - 12	ug/dL
TSH-Ultrasensitive	8.93	0.32 - 5.5	uIU/mL
Method : CLIA			

Interpretation

TSH	T3	T4	Suggested Interpretation for the Thyroid Function Tests Pattern
Raised	Within range	Within range	Raised Within Range Within Range .Isolated High TSHespecially in the range of 4.7 to 15 m1U/m1 is commonly associated with Physiological & Biological TSH Variability. Subclinical Autoimmune Hypothyroidism.Intermittent 14 therapy for hypothyroidism .Recovery phase after Non-Thyroidal illness"
Raised	Decreased	Decreased	Chronic Autoimmune Thyroiditis Post thyroidectomy,Post radioiodine Hypothyroid phase of transient thyroiditis"
Raised or within range	Raised	Raised or within range	Interfering antibodies to thyroid hormones (anti-TPO antibodies)Intermittent 14 therapy or T4 overdose •Drug interference- Amiodarone, Heparin,Beta blockers,steroids, anti-epileptics.
Decreased	Raised or within range	Raised or within range	Isolated Low TSH -especially in the range of 0.1 to 0.4 often seen in elderly & Range Range associated with Non-Thyroidal illness .Subclinical Hyperthyroidism .Thyroxine ingestion'
Decreased	Decreased	Decreased	Central Hypothyroidism .Non-Thyroidal illness .Recent treatment for Hyperthyroidism (TSH remains suppressed)"
Decreased	Raised	Raised	Primary Hyperthyroidism (Graves' disease). Multinodular goitre, Toxic nodule •Transient thyroiditis: Postpartum, Silent (lymphocytic), Postviral (granulomatous, subacute, DeQuervain's), Gestational thyrotoxicosis with hyperemesis gravidarum"
Decreased Within Rang	Raised	Within range	T3 toxicosis •Non-Thyroidal illness
Within range	Decreased	Within range	Isolated Low T3-often seen in elderly & associated Non-Thyroidal illness In elderly the drop in 13 level can be upto 25%.

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MR. VENKATRAMANAN N

Age / Gender: 36 years / Male

Patient ID: 96635

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:31 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
GLUCOSE (F)			
Glucose fasting Method : GOD-POD	118.0	Normal: 70 - 120	mg/dL

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MR. VENKATRAMANAN N

Age / Gender: 36 years / Male

Patient ID: 96635

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:31 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
GLUCOSE (PP) Blood Glucose-Post Prandial Method: GOD-POD	150.0	80 - 140	mg/dL

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,

